Marco Bicchetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marco Bicchetti has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Valeria Panebianco
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy
6 shared publications - Carlo Catalano
Department of Radiological Sciences, Oncology and Pathology, Policlinico Umberto I, Sapienza University, Rome, Italy
4 shared publications - Martina Pecoraro
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy
4 shared publications - Emanuele Messina
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy
3 shared publications - Francesco Del Giudice
Department of Engineering, University of Basilicata, Ateneo Lucano Avenue 10, 85100 Potenza, Italy
3 shared publications - Nicholas Landini
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in La radiologia medica
- Vol. 131 (10) , 1886-1897
Head-to-head comparison of MRI-based PI-RR scoring system and 68 Ga-PSMA-PET/CT: enhancing prostate cancer recurrence detection after radical prostatectomy
Purpose: To compare the diagnostic performance of MRI using the PI-RR scoring system and PSMA-PET/CT in detecting prostate cancer (PCa) local recurrence after radical prostatectomy (RP), and to identify clinical and imaging variables independently associated with recurrence. Materials and Methods: This retrospective, multicenter study evaluated 119 patients with suspected PCa recurrence who underwent both MRI and PSMA-PET/CT; MRI was performed within a time window ranging from up to 3 months before to a maximum of 1 month after the PET/CT examination; the time range was defined within MDTs. Both radiologists and nuclear medicine physicians were blinded to clinical and opposite imaging data during image interpretation. Exclusion criteria included insufficient follow-up, recent pelvic radiation (within 6 months), and history of hormone therapy. Reference standard was defined using histopathologic findings, follow-up imaging, or clinical response to treatment. Sensitivity, specificity, PPV, NPV, and accuracy were calculated. The Cohen’s kappa coefficient was used to determine inter-reader agreement. Univariable and multivariable logistic regression analyses were performed. Results: MRI, considering a PI-RR ≥ 3, detected recurrence in 69 patients versus 48 with PSMA-PET/CT ( p = 0.006). MRI showed significantly higher sensitivity (86%, 95% CI 75–92% vs. 71%, 95% CI 59–80%; p = 0.03) and a trend toward higher specificity (78%, 95% CI 65–87% vs. 52%, 95% CI 39–65%; p = 0.06), PPV (74% vs. 51%), NPV (89% vs. 73%). Overall accuracy was also superior for MRI (81%, 95% CI 74–87% vs. 63%, 95% CI 54–71%). ROC analysis confirmed a higher AUC for MRI (0.87, 95% CI 0.80–0.93) compared with PSMA-PET/CT (0.62, 95% CI 0.52–0.72; ΔAUC = 0.25, p < 0.001). Multivariable analysis showed that only age ( p = 0.002) and PI-RR score ≥ 3 ( p = 0.001) were independently correlated with recurrence. Postoperative risk grouping was correlated only at univariable analysis. Among the 119 included patients, histopathologic confirmation was available in 3% ( n = 4), treatment response (either biochemical or imaging based) in 31% (n = 37), follow-up with imaging in 33% ( n = 39), and clinical-laboratory follow-up in 33% ( n = 39).The median follow-up was 12 months (IQR, 9–18). The effective recurrence rate was 58%. Conclusions: MRI demonstrated strong diagnostic performance in detecting prostate cancer local recurrence. These findings suggest that MRI may be particularly useful for rule out local recurrence in low-risk patients, while PET/CT could be more appropriate for rule in, both local and distant in higher-risk patients. However, this proposed risk-adapted imaging strategy should be considered hypothesis-generating and warrants further validation through prespecified risk-stratified analyses. Limitations include the retrospective design, the composite reference standard, and the relatively high recurrence prevalence, which may have influenced predictive values.
- 25 September 2026
- Published by Springer Nature in La radiologia medica
- Vol. 131 (10) , 1886-1897
Open AccessHead-to-head comparison of MRI-based PI-RR scoring system and 68 Ga-PSMA-PET/CT: enhancing prostate cancer recurrence detection after radical prostatectomy
Purpose: To compare the diagnostic performance of MRI using the PI-RR scoring system and PSMA-PET/CT in detecting prostate cancer (PCa) local recurrence after radical prostatectomy (RP), and to identify clinical and imaging variables independently associated with recurrence. Materials and Methods: This retrospective, multicenter study evaluated 119 patients with suspected PCa recurrence who underwent both MRI and PSMA-PET/CT; MRI was performed within a time window ranging from up to 3 months before to a maximum of 1 month after the PET/CT examination; the time range was defined within MDTs. Both radiologists and nuclear medicine physicians were blinded to clinical and opposite imaging data during image interpretation. Exclusion criteria included insufficient follow-up, recent pelvic radiation (within 6 months), and history of hormone therapy. Reference standard was defined using histopathologic findings, follow-up imaging, or clinical response to treatment. Sensitivity, specificity, PPV, NPV, and accuracy were calculated. The Cohen’s kappa coefficient was used to determine inter-reader agreement. Univariable and multivariable logistic regression analyses were performed. Results: MRI, considering a PI-RR ≥ 3, detected recurrence in 69 patients versus 48 with PSMA-PET/CT ( p = 0.006). MRI showed significantly higher sensitivity (86%, 95% CI 75–92% vs. 71%, 95% CI 59–80%; p = 0.03) and a trend toward higher specificity (78%, 95% CI 65–87% vs. 52%, 95% CI 39–65%; p = 0.06), PPV (74% vs. 51%), NPV (89% vs. 73%). Overall accuracy was also superior for MRI (81%, 95% CI 74–87% vs. 63%, 95% CI 54–71%). ROC analysis confirmed a higher AUC for MRI (0.87, 95% CI 0.80–0.93) compared with PSMA-PET/CT (0.62, 95% CI 0.52–0.72; ΔAUC = 0.25, p < 0.001). Multivariable analysis showed that only age ( p = 0.002) and PI-RR score ≥ 3 ( p = 0.001) were independently correlated with recurrence. Postoperative risk grouping was correlated only at univariable analysis. Among the 119 included patients, histopathologic confirmation was available in 3% ( n = 4), treatment response (either biochemical or imaging based) in 31% (n = 37), follow-up with imaging in 33% ( n = 39), and clinical-laboratory follow-up in 33% ( n = 39).The median follow-up was 12 months (IQR, 9–18). The effective recurrence rate was 58%. Conclusions: MRI demonstrated strong diagnostic performance in detecting prostate cancer local recurrence. These findings suggest that MRI may be particularly useful for rule out local recurrence in low-risk patients, while PET/CT could be more appropriate for rule in, both local and distant in higher-risk patients. However, this proposed risk-adapted imaging strategy should be considered hypothesis-generating and warrants further validation through prespecified risk-stratified analyses. Limitations include the retrospective design, the composite reference standard, and the relatively high recurrence prevalence, which may have influenced predictive values.
- Open Access
- 12 September 2023
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 54 (1) , 1-5
“Cheerios in the lung” as first metastases from endometrial endometrioid adenocarcinoma with adequate response to immunotherapy
Background: Metastases from endometrial carcinoma to the lungs are uncommon and cavitating metastases are even rarer. In some cases, lung cavitating metastases may resemble diffuse “Cheerios in the lung.” Case presentation: A 58-year-old woman, smoker, with a history of hysteroannessiectomy and pelvic lymphadenectomy for a low stage endometrial endometrioid adenocarcinoma, came under our attention for dry cough without fever that persisted for over three months, and computed tomography (CT) revealed diffuse cavitating lung metastases resembling "Cheerios in the lung". After standard chemotherapy proved ineffective, Lenvatinib plus Pembrolizumab (immunotherapy) was administrated, leading to the disappearance of all lung nodules, leaving behind a diffuse emphysematous-like pattern. Conclusions: This case is a rare example of metastatic endometrioid adenocarcinoma, manifested with chronic dry cough, with “Cheerios in the lung” appearence. The metastases responded well to immunotherapy, resulting in the regression of nodules into areas of diffuse emphysematous-like changes.
- 12 September 2023
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 54 (1) , 1-5
Open Access“Cheerios in the lung” as first metastases from endometrial endometrioid adenocarcinoma with adequate response to immunotherapy
Background: Metastases from endometrial carcinoma to the lungs are uncommon and cavitating metastases are even rarer. In some cases, lung cavitating metastases may resemble diffuse “Cheerios in the lung.” Case presentation: A 58-year-old woman, smoker, with a history of hysteroannessiectomy and pelvic lymphadenectomy for a low stage endometrial endometrioid adenocarcinoma, came under our attention for dry cough without fever that persisted for over three months, and computed tomography (CT) revealed diffuse cavitating lung metastases resembling "Cheerios in the lung". After standard chemotherapy proved ineffective, Lenvatinib plus Pembrolizumab (immunotherapy) was administrated, leading to the disappearance of all lung nodules, leaving behind a diffuse emphysematous-like pattern. Conclusions: This case is a rare example of metastatic endometrioid adenocarcinoma, manifested with chronic dry cough, with “Cheerios in the lung” appearence. The metastases responded well to immunotherapy, resulting in the regression of nodules into areas of diffuse emphysematous-like changes.
- Open Access
- 5 October 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1131) , 20210528
MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques
Objectives: To compare the detection rates of overall prostate cancer (PCa) and clinically significant PCa (csPCa) and the median percentage of cancer per biopsy core between MRI-guided In-bore and MRI-TRUS fusion-targeted biopsy (TBx). Methods: In this retrospective study, 223 patients who underwent prostate multiparametric MRI (mpMRI) and subsequent MR-directed biopsy were included. For PCa and csPCa detection rate (DR), contingency tables were tested via the Pearson’s chi-squared to explore the variance of the outcome distribution. The percentage of cancer per biopsy core was tested with a two-tailed Mann-Withney test. Results: One hundred and seventeen and 106 patients underwent MRI-TRUS fusion or MRI In-bore TBx, respectively. 402 MRI biopsy targets were identified, of which 206 (51.2%) were biopsied with the MRI-TRUS TBx and 196 (48.8%) with the MRI In-bore TBx technique. Per-patient PCa and csPCa detection rates were 140/223 (62.8%) and 97/223 (43.5%), respectively. PCa-DR was 73/117 (62.4%) and 67/106 (63.2%) for MRI-TRUS and MRI In-Bore TBx (p = 0.9), while csPCa detection rate reached 50/117 (42.7%) and 47/106 (44.3%), respectively (p = 0.81). The median per-patient percentage of malignant tissue within biopsy cores was 50% (IQR: 27–65%) for PCa and 60% (IQR: 35–68%) for csPCa, with a statistically significant difference between the techniques. Conclusion: No statistically significant difference in the detection rate of MRI In-bore and MRI-TRUS fusion TBx was found. MRI In-bore TBx showed higher per-core percentage of malignant cells. Advances in knowledge: MRI In-bore biopsy might impact risk stratification and patient management considering the higher per-core percentage of malignant cells, especially for patients eligible for active surveillance or focal therapy.
- 5 October 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1131) , 20210528
Open AccessMRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques
Objectives: To compare the detection rates of overall prostate cancer (PCa) and clinically significant PCa (csPCa) and the median percentage of cancer per biopsy core between MRI-guided In-bore and MRI-TRUS fusion-targeted biopsy (TBx). Methods: In this retrospective study, 223 patients who underwent prostate multiparametric MRI (mpMRI) and subsequent MR-directed biopsy were included. For PCa and csPCa detection rate (DR), contingency tables were tested via the Pearson’s chi-squared to explore the variance of the outcome distribution. The percentage of cancer per biopsy core was tested with a two-tailed Mann-Withney test. Results: One hundred and seventeen and 106 patients underwent MRI-TRUS fusion or MRI In-bore TBx, respectively. 402 MRI biopsy targets were identified, of which 206 (51.2%) were biopsied with the MRI-TRUS TBx and 196 (48.8%) with the MRI In-bore TBx technique. Per-patient PCa and csPCa detection rates were 140/223 (62.8%) and 97/223 (43.5%), respectively. PCa-DR was 73/117 (62.4%) and 67/106 (63.2%) for MRI-TRUS and MRI In-Bore TBx (p = 0.9), while csPCa detection rate reached 50/117 (42.7%) and 47/106 (44.3%), respectively (p = 0.81). The median per-patient percentage of malignant tissue within biopsy cores was 50% (IQR: 27–65%) for PCa and 60% (IQR: 35–68%) for csPCa, with a statistically significant difference between the techniques. Conclusion: No statistically significant difference in the detection rate of MRI In-bore and MRI-TRUS fusion TBx was found. MRI In-bore TBx showed higher per-core percentage of malignant cells. Advances in knowledge: MRI In-bore biopsy might impact risk stratification and patient management considering the higher per-core percentage of malignant cells, especially for patients eligible for active surveillance or focal therapy.
- Open Access
The future direction of imaging in prostate cancer: MRI with or without contrast injection
Background: Multiparametric MRI (mpMRI) is the “state of the art” management tool for patients with suspicion of prostate cancer (PCa). The role of non‐contrast MRI is investigated to move toward a more personalized, less invasive, and highly cost‐effective PCa diagnostic workup.Objective: To perform a non‐systematic review of the existing literature to highlight strength and flaws of performing non‐contrast MRI, and to provide a critical overview of the international scientific production on the topic.Materials and Methods: Online databases (Medline, PubMed, and Web of Science) were searched for original articles, systematic review and meta‐analysis, and expert opinion papers.Results: Several investigations have shown comparable diagnostic accuracy of biparametric (bpMRI) and mpMRI for the detection of PCa. The advantage of abandoning contrast‐enhanced sequences improves operational logistics, lowering costs, acquisition time, and side effects. The main limitations of bpMRI are that most studies comparing non‐contrast with contrast MRI come from centers with high expertise that might not be reproducible in the general community setting; besides, reduced protocols might be insufficient for estimation of the intra‐ and extra‐prostatic extension and regional disease. The mentioned observations suggest that low‐quality mpMRI for the general population might represent the main shortage to overcome.Discussion: Non‐contrast MRI future trends are likely represented by PCa screening and the application of artificial intelligence (AI) tools. PCa screening is still a controversial topic; bpMRI has become one of the most promising diagnostic applications, as it is a more sensitive test for PCa early detection, compared to serum PSA level test. Also, AI applications and radiomic have been the object of several studies investigating PCa detection using bpMRI, showing encouraging results.Conclusion: Today, the accessibility to MRI for early detection of PCa is a priority. Results from prospective, multicenter, multireader, and paired validation studies are needed to provide evidence supporting its role in the clinical practice.
Open AccessThe future direction of imaging in prostate cancer: MRI with or without contrast injection
Background: Multiparametric MRI (mpMRI) is the “state of the art” management tool for patients with suspicion of prostate cancer (PCa). The role of non‐contrast MRI is investigated to move toward a more personalized, less invasive, and highly cost‐effective PCa diagnostic workup.Objective: To perform a non‐systematic review of the existing literature to highlight strength and flaws of performing non‐contrast MRI, and to provide a critical overview of the international scientific production on the topic.Materials and Methods: Online databases (Medline, PubMed, and Web of Science) were searched for original articles, systematic review and meta‐analysis, and expert opinion papers.Results: Several investigations have shown comparable diagnostic accuracy of biparametric (bpMRI) and mpMRI for the detection of PCa. The advantage of abandoning contrast‐enhanced sequences improves operational logistics, lowering costs, acquisition time, and side effects. The main limitations of bpMRI are that most studies comparing non‐contrast with contrast MRI come from centers with high expertise that might not be reproducible in the general community setting; besides, reduced protocols might be insufficient for estimation of the intra‐ and extra‐prostatic extension and regional disease. The mentioned observations suggest that low‐quality mpMRI for the general population might represent the main shortage to overcome.Discussion: Non‐contrast MRI future trends are likely represented by PCa screening and the application of artificial intelligence (AI) tools. PCa screening is still a controversial topic; bpMRI has become one of the most promising diagnostic applications, as it is a more sensitive test for PCa early detection, compared to serum PSA level test. Also, AI applications and radiomic have been the object of several studies investigating PCa detection using bpMRI, showing encouraging results.Conclusion: Today, the accessibility to MRI for early detection of PCa is a priority. Results from prospective, multicenter, multireader, and paired validation studies are needed to provide evidence supporting its role in the clinical practice.
- Open Access
Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection
The Vesical Imaging-Reporting and Data System (VI-RADS) has been introduced to provide preoperative bladder cancer staging and has proved to be reliable in assessing the presence of muscle invasion in the pre-TURBT (trans-urethral resection of bladder tumor). We aimed to assess through a systematic review and meta-analysis the inter-reader variability of VI-RADS criteria for discriminating non-muscle vs. muscle invasive bladder cancer (NMIBC, MIBC). PubMed, Web of Science, Cochrane, and Embase were searched up until 30 July 2020. The Quality Appraisal of Diagnostic Reliability (QAREL) checklist was utilized to assess the quality of included studies and a pooled measure of inter-rater reliability (Cohen’s Kappa [κ] and/or Intraclass correlation coefficients (ICCs)) was calculated. Further sensitivity analysis, subgroup analysis, and meta-regression were conducted to investigate the contribution of moderators to heterogeneity. In total, eight studies between 2018 and 2020, which evaluated a total of 1016 patients via 21 interpreting genitourinary (GU) radiologists, met inclusion criteria and were critically examined. No study was considered to be significantly flawed with publication bias. The pooled weighted mean κ estimate was 0.83 (95%CI: 0.78–0.88). Heterogeneity was present among the studies (Q = 185.92, d.f. = 7, p < 0.001; I2 = 92.7%). Meta-regression analyses showed that the relative % of MIBC diagnosis and cumulative reader’s experience to influence the estimated outcome (Coeff: 0.019, SE: 0.007; p= 0.003 and 0.036, SE: 0.009; p = 0.001). In the present study, we confirm excellent pooled inter-reader agreement of VI-RADS to discriminate NMIBC from MIBC underlying the importance that standardization and reproducibility of VI-RADS may confer to multiparametric magnetic resonance (mpMRI) for preoperative BCa staging.
Open AccessSystematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection
The Vesical Imaging-Reporting and Data System (VI-RADS) has been introduced to provide preoperative bladder cancer staging and has proved to be reliable in assessing the presence of muscle invasion in the pre-TURBT (trans-urethral resection of bladder tumor). We aimed to assess through a systematic review and meta-analysis the inter-reader variability of VI-RADS criteria for discriminating non-muscle vs. muscle invasive bladder cancer (NMIBC, MIBC). PubMed, Web of Science, Cochrane, and Embase were searched up until 30 July 2020. The Quality Appraisal of Diagnostic Reliability (QAREL) checklist was utilized to assess the quality of included studies and a pooled measure of inter-rater reliability (Cohen’s Kappa [κ] and/or Intraclass correlation coefficients (ICCs)) was calculated. Further sensitivity analysis, subgroup analysis, and meta-regression were conducted to investigate the contribution of moderators to heterogeneity. In total, eight studies between 2018 and 2020, which evaluated a total of 1016 patients via 21 interpreting genitourinary (GU) radiologists, met inclusion criteria and were critically examined. No study was considered to be significantly flawed with publication bias. The pooled weighted mean κ estimate was 0.83 (95%CI: 0.78–0.88). Heterogeneity was present among the studies (Q = 185.92, d.f. = 7, p < 0.001; I2 = 92.7%). Meta-regression analyses showed that the relative % of MIBC diagnosis and cumulative reader’s experience to influence the estimated outcome (Coeff: 0.019, SE: 0.007; p= 0.003 and 0.036, SE: 0.009; p = 0.001). In the present study, we confirm excellent pooled inter-reader agreement of VI-RADS to discriminate NMIBC from MIBC underlying the importance that standardization and reproducibility of VI-RADS may confer to multiparametric magnetic resonance (mpMRI) for preoperative BCa staging.
- 23 July 2020
- Published by Wiley in BJU International
- Vol. 126 (5) , 610-619
Preoperative detection of Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?
Objectives: (I) To determine Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 accuracy in predicting locally advanced bladder cancer (BCa), so as to potentially identify those patients who could avoid the morbidity of deep transurethral resection of bladder tumour (TURBT) in favour of histological sampling‐TUR prior to radical cystectomy (RC). (II) To explore the predictive value of VI‐RADS score 5 on time‐to‐cystectomy (TTC) outcomes. Patients and Methods: We retrospectively reviewed patients’ ineligible or refusing cisplatin‐based combination neoadjuvant chemotherapy who underwent multiparametric magnetic resonance imaging (mpMRI) of the bladder prior to staging TURBT followed by RC for muscle‐invasive BCa. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated for VI‐RADS score 5 vs. score 2–4 cases to assess the accuracy of mpMRI for extravesical BCa detection (≥pT3). VI‐RADS score performance was assessed by receiver operating characteristics curve analysis. A Κ statistic was calculated to estimate mpMRI and pathological diagnostic agreement. The risk of delayed TTC (i.e. time from initial BCa diagnosis of >3 months) was assessed using multivariable logistic regression model. Results: A total of 149 T2–T4a, cN0–M0 patients (VI‐RADS score 5, n = 39 vs VI‐RADS score 2–4, n = 110) were examined. VI‐RADS score 5 demonstrated sensitivity, specificity, PPV and NPV, in detecting extravesical disease of 90.2% (95% confidence interval [CI] 84–94.3), 98.1% (95% CI 94–99.6), 94.9% (95% CI 89.6–97.6) and 96.4% (95% CI 91.6–98.6), respectively. The area under the curve was 94.2% (95% CI 88.7–99.7) and inter‐reader agreement was excellent (Κ inter 0.89). The mean (SD) TTC was 4.2 (2.3) and 2.8 (1.1) months for score 5 vs 2–4, respectively ( P < 0.001). VI‐RADS score 5 was found to independently increase risk of delayed TTC (odds ratio 2.81, 95% CI 1.20–6.62). Conclusion: The VI‐RADS is valid and reliable in differentiating patients with extravesical disease from those with muscle‐confined BCa before TURBT. Detection of VI‐RADS score 5 was found to predict significant delay in TTC independently from other clinicopathological features. In the future, higher VI‐RADS scores could potentially avoid the morbidity of extensive primary resections in favour of sampling‐TUR for histology. Further prospective, larger, and multi‐institutional trials are required to validate clinical applicability of our findings.
- 23 July 2020
- Published by Wiley in BJU International
- Vol. 126 (5) , 610-619
Preoperative detection of Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?
Objectives: (I) To determine Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 accuracy in predicting locally advanced bladder cancer (BCa), so as to potentially identify those patients who could avoid the morbidity of deep transurethral resection of bladder tumour (TURBT) in favour of histological sampling‐TUR prior to radical cystectomy (RC). (II) To explore the predictive value of VI‐RADS score 5 on time‐to‐cystectomy (TTC) outcomes. Patients and Methods: We retrospectively reviewed patients’ ineligible or refusing cisplatin‐based combination neoadjuvant chemotherapy who underwent multiparametric magnetic resonance imaging (mpMRI) of the bladder prior to staging TURBT followed by RC for muscle‐invasive BCa. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated for VI‐RADS score 5 vs. score 2–4 cases to assess the accuracy of mpMRI for extravesical BCa detection (≥pT3). VI‐RADS score performance was assessed by receiver operating characteristics curve analysis. A Κ statistic was calculated to estimate mpMRI and pathological diagnostic agreement. The risk of delayed TTC (i.e. time from initial BCa diagnosis of >3 months) was assessed using multivariable logistic regression model. Results: A total of 149 T2–T4a, cN0–M0 patients (VI‐RADS score 5, n = 39 vs VI‐RADS score 2–4, n = 110) were examined. VI‐RADS score 5 demonstrated sensitivity, specificity, PPV and NPV, in detecting extravesical disease of 90.2% (95% confidence interval [CI] 84–94.3), 98.1% (95% CI 94–99.6), 94.9% (95% CI 89.6–97.6) and 96.4% (95% CI 91.6–98.6), respectively. The area under the curve was 94.2% (95% CI 88.7–99.7) and inter‐reader agreement was excellent (Κ inter 0.89). The mean (SD) TTC was 4.2 (2.3) and 2.8 (1.1) months for score 5 vs 2–4, respectively ( P < 0.001). VI‐RADS score 5 was found to independently increase risk of delayed TTC (odds ratio 2.81, 95% CI 1.20–6.62). Conclusion: The VI‐RADS is valid and reliable in differentiating patients with extravesical disease from those with muscle‐confined BCa before TURBT. Detection of VI‐RADS score 5 was found to predict significant delay in TTC independently from other clinicopathological features. In the future, higher VI‐RADS scores could potentially avoid the morbidity of extensive primary resections in favour of sampling‐TUR for histology. Further prospective, larger, and multi‐institutional trials are required to validate clinical applicability of our findings.